Barchart Research What to Expect from ACHV Earnings ACHV Generated August 12, 2026 Current Price $6.69 EPS Estimate $$-0.19 Consensus Rating Strong Buy Average Move 6.69% Achieve Life Sciences Approaches...
Achieve Life Sciences (ACHV) is a $685 million biotech focused on cytisinicline-based nicotine addiction treatments, showing strong recent technical momentum. ACHV has surged 173% over 52 weeks. Shares...
Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened...
Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading...
Barchart Research What to Expect from ACHV Earnings ACHV Generated August 5, 2026 Current Price $6.66 EPS Estimate $$-0.18 Consensus Rating Strong Buy Average Move 6.69% Achieve Life Sciences Nears Regulatory...
Veteran U.S.-based CMC, supply chain, and quality leaders join Achieve as the Company continues the transition of cytisinicline finished product...
SEATTLE and VANCOUVER, British Columbia, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on...
SEATTLE and VANCOUVER, British Columbia, July 31, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development...
SEATTLE and VANCOUVER, British Columbia, July 31, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty...
SEATTLE and VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on...